FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up

FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing